<span id="midArticle_start"/> Novartis AG
<span id="midArticle_0"/>* Novartis said new one-year data for secukinumab, the firstIL-17A inhibitor to show significant improvement in ankylosingspondylitis (AS) signs and symptoms, was to be presented atEuropean League Against Rheumatism meeting (EULAR)
<span id="midArticle_1"/> <span class="first-article-divide"/>* Data from the Phase III MEASURE 2 study demonstratesecukinumab improves the signs and symptoms of AS diseaseactivity through one year of treatment, confirming previousone-year data from the MEASURE 1 study
<span id="midArticle_2"/> <span class="second-article-divide"/>* AS is a long-term, painful and progressively debilitatinginflammatory disease that leads to excessive formation of newbone, particularly in the joints of the spine, which can fusetogether
<span id="midArticle_3"/> <span class="third-article-divide"/>* Novartis says Cosentyx (secukinumab) data to be revealedin patients with difficult-to-treat psoriasis of the palms,soles and nails at World Congress of Dermatology (WCD)Further company coverage: (Reporting By Zurich Slot)
<span id="midArticle_4"/>
<span id="midArticle_0"/>* Novartis said new one-year data for secukinumab, the firstIL-17A inhibitor to show significant improvement in ankylosingspondylitis (AS) signs and symptoms, was to be presented atEuropean League Against Rheumatism meeting (EULAR)
<span id="midArticle_1"/> <span class="first-article-divide"/>* Data from the Phase III MEASURE 2 study demonstratesecukinumab improves the signs and symptoms of AS diseaseactivity through one year of treatment, confirming previousone-year data from the MEASURE 1 study
<span id="midArticle_2"/> <span class="second-article-divide"/>* AS is a long-term, painful and progressively debilitatinginflammatory disease that leads to excessive formation of newbone, particularly in the joints of the spine, which can fusetogether
<span id="midArticle_3"/> <span class="third-article-divide"/>* Novartis says Cosentyx (secukinumab) data to be revealedin patients with difficult-to-treat psoriasis of the palms,soles and nails at World Congress of Dermatology (WCD)Further company coverage: (Reporting By Zurich Slot)
<span id="midArticle_4"/>
via Smart Health Shop Forum http://ift.tt/1AHKJK5
No comments:
Post a Comment